The archive · Bio & Materials · Product decision · 2015–2026
Paradromics' Connexus bet: first speech-restoring BCI implant lands in an FDA study
Paradromics bet a high-density wireless brain implant could win FDA study approval; it did in Nov 2025, and its first participant was implanted in June 2026.
Paradromics
What the business is
Paradromics builds the Connexus BCI: a brain implant with hundreds of microelectrodes that records neural signals and sends them through a chest transceiver to text or synthesized speech.
Starting capital：$33 million Series A announced 2023-05-18, led by Prime Movers Lab (CNBC).
How it started
Matt Angle, a neuroscientist, founded Paradromics in Austin in 2015. Its Connexus platform records from hundreds of neurons; the company positioned it as an assistive communication device translating thought into text or synthesized speech.
What happened
The FDA granted Breakthrough Device designation in March 2023, and CNBC reported the company hoped to open its first human trial in the first half of 2024. A temporary Connexus implant in June 2025, during epilepsy research at U-M Health, confirmed the device could sit in the brain and record signals safely.
How it ended up
On 2026-06-16 neurosurgeons at University of Michigan Health implanted Connexus in the first participant of the FDA-approved Connect-One Early Feasibility Study, a Michigan woman with motor neuron disease who struggles to speak; she will be followed for six years.
Background
Paradromics was founded in Austin in 2015 by Matt Angle to build a brain-computer interface that could restore communication for people who have lost the ability to speak. Its Connexus system records neural signals through an implant carrying hundreds of microelectrodes and sends them wirelessly through a transceiver under the skin of the chest.
In March 2023 the FDA gave Connexus Breakthrough Device designation, and on 2023-05-18 Paradromics announced a $33 million round led by Prime Movers Lab. CNBC framed it as the engineering-heavy rival to Neuralink: invasive electrodes inside the brain tissue, chosen for signal quality over the gentler approaches used by competitors such as Synchron.
The company needed two more regulatory steps before its first patient. After an Investigational Device Exemption in November 2025, clinical teams at University of Michigan Health, UC Davis and Massachusetts General Hospital began screening. A temporary implant during epilepsy research in June 2025 had already shown the device could be placed in the brain and record signals.
On 2026-06-16, neurosurgeons at University of Michigan Health implanted Connexus in the first Connect-One study participant, a Michigan woman with motor neuron disease who struggles to speak. The early feasibility study will follow her for six years while testing whether the device restores text and synthesized speech and enables computer control.
What has to be true
- The FDA process is the real product roadmap: each designation, exemption and study approval converts a research device into something hospitals can actually enroll patients around.
- Paradromics picked an unmet need with measurable value: a person who cannot speak gains agency through communication, which is the emotional and clinical core of the pitch.
- A fully implantable wireless design, with signal routed through the chest, is a differentiation bet that also simplifies daily use for a participant living with severe motor impairment.
- Announcing milestones in step with regulators, not just engineers, is what kept coverage alive from the 2023 designation through the 2026 first-in-human implant.
What can be applied
In regulated deep tech, the milestone that unlocks value is the regulatory one: Breakthrough designation built an FDA relationship that carried a young company into first-in-human study.
Aftermath
As of 2026-06-17, Paradromics is running the Connect-One Early Feasibility Study at three US sites with one implanted participant and a six-year follow-up plan. The study is the first in a planned series of clinical applications for the Connexus platform, and Paradromics says it is building toward next-generation clinical BCIs rather than a single product launch.
Sources
- Neuralink competitor Paradromics gets one step closer to FDA approval for its brain implant
- U-M Health neurosurgeons complete first human implant of wireless brain computer interface
- Paradromics and University of Michigan complete first Connexus BCI implantation in clinical study
spotted an error? The archive wants to know.
Your turn
You just read one. Describe what you are building, and see who is betting on the same thing.
Free account · 3 free questions · no card